nejm glp 1 GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read An Oral GLP-1 Receptor Agonist

This guide explores prescription options, compounded alternatives, and how genetic and biomarker factors may inform provider conversations about suitability

New research suggests that switching to a maintenance dose of GLP-1 medication could help lock in weight loss.

I can play with my grandchildren again, and Im even considering getting back on the tennis court

For the first time, Medicare will cover GLP-1s for obesity-related weight loss, without any other medical conditions.

Increased sweating affects some semaglutide users during treatment

As of early 2026, several potent single, dual, and triple incretin receptor agonists are in Phase 2/3 trials for MASH including : Survodutide : A dual glucagon (GCGR)/GLP-1 receptor agonist that has shown significant MASH resolution in Phase 2 trials